Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

14.40 -0.46 (-3.13%)
Streaming Delayed Price Updated: 3:28 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
News headline image
Why Novocure Stock Was so Healthy Today ↗
There was good news from the laboratory on Hump Day. 
Via The Motley Fool
News headline image
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Why Novocure Stock Is Sliding Today ↗
Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs. 
Via The Motley Fool
News headline image
Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes ↗
A series of unexpected C-suite changes sent shares diving again. 
Via Investor's Business Daily
News headline image
Novocure Announces Organizational Changes to Prepare for Future Growth
From Novocure
Via Business Wire
News headline image
Will Novocure Stock Sink or Soar in 2023? ↗
The stock has both soared and sank already this year. 
Via The Motley Fool
News headline image
Why Novocure Stock Is Sinking Today ↗
The company provided a disappointing sneak peek at its Q4 results. 
Via The Motley Fool
News headline image
Why Novocure Stock Is Flying High ↗
Here's why Novocure stock popped over 68% on Jan. 5. 
Via The Motley Fool
News headline image
Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace ↗
Shares have given back a chunk of their 69% single-day gain on a lung cancer study. 
Via Investor's Business Daily
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
News headline image
Is NovoCure a Good Stock to Buy Right Now? ↗
Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead? 
Via The Motley Fool
News headline image
Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review ↗
The major indexes rallied Friday on the jobs report and services data. 
Via Investor's Business Daily
News headline image
Why Novocure Stock Is Skyrocketing Today ↗
The company announced good news from a late-stage study of its Tumor Treating Fields therapy. 
Via The Motley Fool
News headline image
Novocure Skyrockets After Pulling Off A Once-In-Six-Years Feat ↗
The company is now planning to ask for FDA approval in the second half of 2023. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
News headline image
Tesla, Amazon, Aehr, Silvergate, Novocure: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
Major Wall Street indices closed over 1% lower on Thursday, dragged by strong employment data which could nudge the Federal Reserve to continue its rate hikes. 
Via Benzinga
News headline image
Why Shares of Zai Lab Soared This Week ↗
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company. 
Via The Motley Fool
News headline image
Dow Falls Over 200 Points; Walgreens Earnings Top Expectations ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 200 points on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Down Over 100 Points; Crude Oil Rises 1% ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday. 
Via Benzinga
News headline image
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization... 
Via Benzinga
News headline image
Why Is Huadi International (HUDI) Stock Up 30% Today? ↗
Huadi International (HUDI) stock is climbing higher on Thursday even without specific news from the Chinese steel company. 
Via InvestorPlace
News headline image
Why Is Magic Empire Global (MEGL) Stock Up 83% Today? ↗
Magic Empire Global (MEGL) stock is rocketing higher on Thursday despite a lack of news from the Hong Kong financial services provider. 
Via InvestorPlace
News headline image
NovoCure (NVCR) Stock Soars 50% on Positive Clinical Trial Results ↗
NVCR stock traders are undeniably pleased to see NovoCure marking a milestone in the company's quest to treat a specific type of lung cancer. 
Via InvestorPlace
News headline image
Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients ↗
 
Via Benzinga
News headline image
This Good News on Cancer Sent 2 Nasdaq Stocks Soaring ↗
Biotech investors are optimistic about the prospects for a potential treatment. 
Via The Motley Fool
News headline image
US Stocks Open Lower; Dow Tumbles 300 Points ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 300 points on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Zai Lab Limited
Via GlobeNewswire
News headline image
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Novocure
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.